Business Description
BioXcel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US09075P1057
Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | -0.77 | |||||
| Debt-to-Equity | -1.79 | |||||
| Debt-to-EBITDA | -0.61 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -17.53 | |||||
| Beneish M-Score | 2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | -16.6 | |||||
| 3-Year FCF Growth Rate | -20.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 191.72 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.16 | |||||
| 9-Day RSI | 36.69 | |||||
| 14-Day RSI | 39.81 | |||||
| 6-1 Month Momentum % | 2.24 | |||||
| 12-1 Month Momentum % | -87.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.65 | |||||
| Quick Ratio | 2.57 | |||||
| Cash Ratio | 2.39 | |||||
| Days Inventory | 571.44 | |||||
| Days Sales Outstanding | 93.52 | |||||
| Days Payable | 3096.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 | |||||
| Shareholder Yield % | -76.96 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 8.62 | |||||
| Operating Margin % | -12146.45 | |||||
| Net Margin % | -12974.86 | |||||
| FCF Margin % | -11232.32 | |||||
| ROE % | -2323.67 | |||||
| ROA % | -127.86 | |||||
| ROIC % | -2730.34 | |||||
| ROC (Joel Greenblatt) % | -9373.37 | |||||
| ROCE % | -154.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 54.54 | |||||
| EV-to-EBIT | -0.69 | |||||
| EV-to-Forward-EBIT | -1.22 | |||||
| EV-to-EBITDA | -0.7 | |||||
| EV-to-Forward-EBITDA | -1.29 | |||||
| EV-to-Revenue | 83.37 | |||||
| EV-to-Forward-Revenue | 44.25 | |||||
| EV-to-FCF | -0.74 | |||||
| Earnings Yield (Greenblatt) % | -144.93 | |||||
| FCF Yield % | -198.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BTAI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioXcel Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.38 | ||
| EPS (TTM) ($) | -6.14 | ||
| Beta | 0.37 | ||
| Volatility % | 121.94 | ||
| 14-Day RSI | 39.81 | ||
| 14-Day ATR ($) | 0.184946 | ||
| 20-Day SMA ($) | 2.7285 | ||
| 12-1 Month Momentum % | -87.06 | ||
| 52-Week Range ($) | 1.91 - 29.56 | ||
| Shares Outstanding (Mil) | 30.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioXcel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioXcel Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioXcel Therapeutics Inc Frequently Asked Questions
What is BioXcel Therapeutics Inc(BTAI)'s stock price today?
The current price of BTAI is $2.55. The 52 week high of BTAI is $29.56 and 52 week low is $1.91.
When is next earnings date of BioXcel Therapeutics Inc(BTAI)?
The next earnings date of BioXcel Therapeutics Inc(BTAI) is 2024-05-08 Est..
Does BioXcel Therapeutics Inc(BTAI) pay dividends? If so, how much?
BioXcel Therapeutics Inc(BTAI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers